Clinical Trials on Prophylaxis of Lyme Borreliosis in Belgium

Total 5 results

Pfizer
Valneva Austria GmbH

Completed

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Lyme Borreliosis, Nervous System

Belgium, United States
Pfizer

Completed

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Lyme Borreliosis

United States, Germany, Belgium
ThromboGenics
BioInvent International AB

Completed

Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

Prophylaxis of Venous Thromboembolic Events

Austria, Netherlands, Belgium, Bulgaria, Hungary, Latvia, Poland, Russian Federation, Ukraine
Pfizer
European Society for Blood and Marrow Transplantation

Completed

Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI)

Prophylaxis Of Invasive Fungal Infections

Portugal, Belgium, France, Germany, Spain, United Kingdom, Switzerland, Sweden
Cidara Therapeutics Inc.

Recruiting

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT)

Mycoses | Candidemia | Fungemia | Fungal Infection | Invasive Candidiasis | Invasive Fungal Disease | Pneumocystis | Mold Infection | Prophylaxis of Invasive Fungal Infections | Aspergillus

United States, Germany, France, Belgium, Canada, Italy, Spain, United Kingdom, Turkey, Switzerland

Clinical Trials on Prophylaxis of Lyme Borreliosis in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations